The Phase Ib trial assessed the bespoke cancer vaccine NEO-PV-01 plus Opdivo as a treatment for patients with advanced melanoma, NSCLC, and bladder cancer.
The Norwegian company will receive $200 million upfront from Genentech for the rights to its investigational neoantigen-based cancer vaccine, VB10.NEO.
Investigators saw responses in one colorectal cancer and one breast cancer patient and are now studying differences between responders and non-responders.
The Phase IB trial will test whether UbiVac's cancer vaccine combined with BMS' T cell agonist and Opdivo can stimulate anti-cancer immunity in advanced TNBC patients.
A new study suggests that using rotavirus in combination with immune checkpoint blockade therapy could give oncologists a new way to treat pediatric cancers.
